Cabergoline
کابرگولین
🚻 Genito Urinary System And Sex HormonesDopamine agonist
Market / country: 🇺🇸 USA
Dostinex (US)
🧮 Dose calculator
Hyperprolactinaemia · Regimen source: FDA Cabergoline · 2.2
- • Twice weekly (not daily). Increase by 0.25 mg twice weekly at intervals until prolactin normalises. FDA Cabergoline · 2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Uncontrolled hypertension; hypersensitivity to ergot derivatives; history of cardiac valvulopathy; history of pulmonary, pericardial or retroperitoneal fibrosis. FDA Cabergoline · 4
- ⛔ Ergot hypersensitivity; history of pulmonary, pericardial or retroperitoneal fibrosis; hepatic insufficiency; toxaemia of pregnancy; concomitant antipsychotics; history of puerperal psychosis. UK Dostinex SmPC · 4.3
Formulations
- 0.5 mg tablet (scored) — tablet 🇺🇸 USA FDA Cabergoline · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Cabergoline · 8.1
“Clinical Considerations Maternal Adverse Reactions : In general, avoid use of dopamine agonists, including cabergoline tablets, during pregnancy and the postpartum period.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Cabergoline · 8.2
“Risk Summary Cabergoline tablets is not recommended in postpartum women who are breastfeeding or who are planning to breastfeed.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Cabergoline · 8.4
“Safety and effectiveness of cabergoline tablets in pediatric patients have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Cabergoline · 8.5
“Clinical studies of cabergoline tablets did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA220309
- DailyMed (FDA label)FDA Cabergoline
- MedlinePlus (NIH)Cabergoline
- WHO ATC/DDDG02CB03
- Darooyab (Iran)Cabergoline
- eMC (UK label)UK Dostinex SmPC
🇮🇷 Registered in Iran Darooyab · G-2486/Cabergoline
Dosage forms with Iranian generic codes, per Darooyab.
- 02287 · CABERGULINE 0.5MG TAB · قرص کابرگولین ۰٫۵ میلیگرم
- 02374 · CABERGULINE 1MG TAB · قرص کابرگولین ۱ میلیگرم
- 08822 · CABERGULINE 2MG TAB · قرص کابرگولین ۲ میلیگرم
- 08824 · CABERGULINE 4MG TAB · قرص کابرگولین ۴ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Cabergoline · 3FDA Cabergoline · 2.2FDA Cabergoline · 2FDA Cabergoline · 4FDA Cabergoline · 8.1FDA Cabergoline · 8.2FDA Cabergoline · 8.4FDA Cabergoline · 8.5FDA Cabergoline · SPL approval / marketing category
- UK SmPC (eMC / MHRA)✅ PresentUK Dostinex SmPC · 4.2UK Dostinex SmPC · 4.3
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-2486/Cabergoline
- Clinical review⚠ Unverified